See more : Sirius Real Estate Limited (SRE.L) Income Statement Analysis – Financial Results
Complete financial analysis of Aridis Pharmaceuticals, Inc. (ARDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aridis Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Redbox Entertainment Inc. (RDBXW) Income Statement Analysis – Financial Results
- Consumer Portfolio Services, Inc. (CPSS) Income Statement Analysis – Financial Results
- Paz Oil Company Ltd. (PZOL.TA) Income Statement Analysis – Financial Results
- Eastman Kodak Company (0IF4.L) Income Statement Analysis – Financial Results
- Golden Ocean Group Limited (GOGL) Income Statement Analysis – Financial Results
Aridis Pharmaceuticals, Inc. (ARDS)
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.00M | 1.02M | 2.76M | 860.00K | 2.27M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M |
| Gross Profit | 0.00 | 0.00 | 1.00M | 1.02M | 2.76M | 860.00K | 342.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 15.07% |
| Research & Development | 25.92M | 37.94M | 16.96M | 24.08M | 23.00M | 17.44M | 6.26M |
| General & Administrative | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M |
| Other Expenses | -3.09M | -1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.99M | 43.71M | 23.40M | 30.11M | 26.87M | 20.60M | 8.23M |
| Cost & Expenses | 29.99M | 43.71M | 23.40M | 30.11M | 26.87M | 20.60M | 10.15M |
| Interest Income | 0.00 | 0.00 | 77.00K | 357.00K | 0.00 | 234.00K | 0.00 |
| Interest Expense | 378.00K | -245.00K | 0.00 | 0.00 | 420.00K | 0.00 | 366.00K |
| Depreciation & Amortization | 487.00K | -722.00K | 337.00K | 338.00K | 283.00K | 62.00K | 23.00K |
| EBITDA | -29.51M | -44.43M | -22.06M | -28.75M | -23.83M | -19.68M | -7.86M |
| EBITDA Ratio | 0.00% | 0.00% | -2,240.10% | -2,846.09% | -933.95% | -1,688.84% | -338.87% |
| Operating Income | -29.99M | -43.71M | -22.40M | -29.09M | -24.12M | -19.74M | -7.88M |
| Operating Income Ratio | 0.00% | 0.00% | -2,240.10% | -2,846.09% | -874.76% | -2,295.12% | -347.47% |
| Total Other Income/Expenses | -378.00K | 1.52M | 68.00K | -594.00K | 2.01M | -4.92M | -538.00K |
| Income Before Tax | -30.37M | -43.19M | -22.33M | -29.68M | -22.11M | -24.66M | -8.42M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,233.30% | -2,904.21% | -801.78% | -2,866.98% | -371.18% |
| Income Tax Expense | 378.00K | -912.00K | -414.00K | -695.00K | 2.43M | 4.92M | 538.00K |
| Net Income | -30.75M | -42.28M | -21.92M | -28.99M | -22.11M | -24.66M | -8.42M |
| Net Income Ratio | 0.00% | 0.00% | -2,191.90% | -2,836.20% | -801.78% | -2,866.98% | -371.18% |
| EPS | -1.64 | -3.44 | -2.39 | -3.43 | -7.02 | -3.12 | -1.07 |
| EPS Diluted | -1.64 | -3.44 | -2.39 | -3.43 | -7.02 | -3.12 | -1.07 |
| Weighted Avg Shares Out | 18.78M | 12.29M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
| Weighted Avg Shares Out (Dil) | 18.78M | 12.29M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
Aridis Provides Corporate Update
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Aridis Pharmaceuticals Announces $2 Million Offering
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Source: https://incomestatements.info
Category: Stock Reports